1. Introduction {#s0005}
===============

Considered as an essential "metabolic organ", intestinal microbiome contains more than 1000 bacterial species whose total number is as high as 100 trillion, and has approximately 150 times the genetic capacity of the human genome ([@b0410], [@b0525], [@b0640], [@b0385]). A large section of healthy intestinal microbiome comprises bacteria, with the phyla Firmicutes and Bacteroidetes being the most dominant, and a smaller section is composed of archea, protozoa, viruses and fungi ([@b0125], [@b0405], [@b0610]). These microorganisms colonize the host body from birth, and their diversity then increases considerably at the strain level, to the point where adults have relatively stable gut microbiota ([@b0025]). However, each individual has a specific microbial taxa ([@b0090], [@b0730]), and even twins have \<50% of the same bacterial species ([@b0655]), which is influenced by lots of factors including host genotype ([@b0045]), antibiotic usage ([@b0280], [@b0120]), concomitant diseases ([@b0750]), and the maternal environment ([@b0040]). The unique community is indispensable for maintaining human health ([@b0085]). It can ferment proteins and carbohydrates that are not digested by host into absorbable energy and short chain fatty acids (SCFA) ([@b0535]), maintain mucosal structure to shape the immune response ([@b0020]), synthetize vitamins (B and K) ([@b0135]), and metabolize many endogenous substances including cholesterol, bile acids, tryptophan, neurotransmitters ([@b0340]). These microorganisms and their metabolites are also considered important in metabolizing orally administered exogenous compounds, especially drugs ([@b0275])). Therefore, inter-individual or intra-individual microbial diversity or dysbacteria is of potential clinical significance.

It is well known that the liver is a main organ responsible for pharmaceutical metabolism and biotransformation. However, the metabolism of drug may begin at the intestinal level earlier than that at liver. Great majority of intestinal microbes reside in colon where the quantity of microorganisms is as high as 10^13^. Microbial distribution is characterized by a decrease in the quantity and species of microorganisms from the colon to the stomach ([@b0585]). Oral delivery of medicines, especially those that are not completely absorbed from the small intestine or candidates for enterohepatic circulation, are in inevitable contact with microbiota of the distal gut ([@b0460]). And the metabolic response performed by gut microbiota is completely different from that by the liver. Specifically, the microbiota mainly produces non-polar low-molecular weight metabolites through hydrolytic and reductive metabolism, while the liver primarily generates polar and high-molecular weight byproducts through oxidative and conjugative metabolism ([@b0285], [@b0305]). Thus, the intestinal microbiota affects drug absorption, and changes pharmacological effects of drugs. The effect of gut microbiota on host-targeted drugs efficacy has long been recognised in the late 1930s ([@b0440]), when the sulfa-based antibiotics are identified as substrates for microbial transformation. It is attributed to microbial estimated 3.3 million genes, particularly genes encoding heterogeneous biodegradation and metabolic pathways ([@b0520]). In recent years, a large number of studies on drug metabolism mechanisms have proved that the intestinal microbiota possesses a variety of metabolic activities that are able to modulate the fate of more than 30 approved drugs and their bioavailability ([@b0480], [@b0080], [@b0215]). These medicines are transformed to bioactive, inactive, or toxic metabolite (s) ([@b0275], [@b0740]). For instance, the enzymes from colonic bacteria catalyze the reduction of sulfasalazine into 5-aminosalicylic acid, which induces anti-inflammatory effects ([@b0355], [@b0245]). And gut microbiota metabolizes levamisole into three activity-reduced metabolites ([@b0595]). Other representative examples of pharmaceuticals metabolized by the gut microbiota include diclofenac, omeprazole, digoxin, irinotecan, glycyrrhizin and so on.

In addition, the metabolic association between the host and gut microbiota changes the pharmacokinetics and pharmacodynamics of drugs ([@b0225], [@b0060]), such as acetaminophen. In view of the significant effects on drug metabolism by gut microbiota, this review mainly focus on specific mechanisms involved, with reference to current literature about drugs metabolism whose related bacteria or enzymes are available.

2. Diverse mechanisms of intestinal microflora affecting drug metabolism {#s0010}
========================================================================

In fact, all functional activities performed by humans beings, including drug metabolism, are determined by two sets of genomes -- the genetically inherited human genome and the environmentally acquired microbiome ([@b0395]). Among all environmentally-acquired microorganisms, intestinal microorganisms are most abundant. Accumulating evidences reveal that changes in the gut microbiome are linked to many diseases, including diabetes, obesity ([@b0150]), CDI ([@b0140]), cardiovascular disease ([@b0600]) and inflammatory skin disease (2018). And its diversification contributes to the interindividual differences of results with drugs therapy. Together, a wealth of information is emerging about the roles of the gut microbiota on pharmacokinetics and therapeutic outcomes, particularly on drugs metabolized by particular bacteria or known bacterial enzymes. There are also some medicines that are confirmed to be associated with the intestinal microbiota by animal models, but their associated microbiota and bacterial metabolites are unknown. Due to the differences in the quantity and diversity of intestinal microbiota in animal models and human, and various factors affecting pharmacokinetics *in vivo*, the specific correlation between these medicines and human intestinal microbiota needs further investigation. When we focus on drugs that are clearly related to the intestinal microbiota, we find out the bacteria participate in the biotransformations of administered drugs, even dietary compounds and environmental toxins, through a number of diverse direct or indirect mechanisms ([@b0060], [@b0350]). Several articles have reviewed the effects of gut microbiota on efficacy and toxicity of dietary components and environmental toxins ([@b0615], [@b0720]). The list of drugs and phytochemicals that are metabolized by the specific gut microbiota or microbial enzyme through known mechanism is presented in [Table 1](#t0005){ref-type="table"}.Table 1Drugs and phytochemicals that are metabolized by the specific gut microbiota or microbial enzyme.DrugClinical applicationBacterial Species or enzymes involvedMechanismRef.ProntosilAntibioticsAzoreductasesEnzymatic cleavage of azo-bond to sulfanilamide[@b0235], [@b0240], [@b0245], [@b0250]Neoprontosil[@b0235], [@b0240], [@b0245]SulfasalazineAnti-inflammatory drugsEnzymatic cleavage of azo-bond to sulfanilamide 5-aminosalicylic acid[@b0255]Balsalazide[@b0270]Olsalazine[@b0285]  MetronidazoleAntibacterial agent*Clostridium perfringens*Enzymatic cleavage of ring to N-(2-hydroxyethyl)-oxamic acid and acetamide[@b0300]  LevamisoleAnthelmintic drug*Bacteroidetes* and *Clostridium* spp.Enzymatic cleavage of ring to levametabol-I, levametabol-II, and levametabol-III[@b0180]  OmeprazoleantiulceroticsAnaerobic bacteria such as *Bacteroides* strainsEnzymatic reduction to corresponding sulfide metabolites[@b0305]  ZonisamideAnticonvulsant*Clostridium sporogenes*Enzymatic reduction of benzisoxazole ring to 2-sulphamoylacetylphenol[@b0310]  LactuloseLaxative drug*Bifidobacterium bifidum*, *Lactobacillus acidophilus*, *Clostridium perfringens*Two enzymatic convertion to lactic and acetic acids[@b0315], [@b0320]Sodium picosulfateArylsulfate sulfotransferase of *Eubacterium rectale*Enzymatic convertion to 4,49-(pyridin-2-ylmethanediyl) diphenol[@b0325], [@b0330]  GlycyrrhizinAntiviral drug*Eubacterium*. sp. strain GLHEnzymatic convertion to 18b-glycyrrhetic acid[@b0340], [@b0345]  BuddleosideAnticancer drugα-l-rhamnosidase and β-d-glucosidase of *Escherichia* sp., *Escherichia* sp., *Enterococcus* sp. and *Bacillus* sp.Two enzymatic convertion to acacetin[@b0350]  Ginsenoside Rb1Health protectionOscillibacter spp., Ruminococcus spp., Holdemania spp., and Sutterella spp.Enzymatic convertion to 20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol[@b0355], [@b0360]  SennosidesLaxative drugReductase and 3-b-D-glucosidaseTwo enzymatic convertion to rheinanthrone[@b0365]  DigoxinCardiotonics*Eggerthella lenta* possessing a two-gene cytochrome-encoding operonEnzymatic convertion to dihydrodigoxin and dihydrodigoxigenin[@b0395], [@b0400], [@b0405], [@b0410]  LevodopaAnti-psychotics*Helicobacter pylori*Enzymatic dehydroxylation to m-tyramine or m-hydroxyphenylacetic acid to sequestering it from brain[@b0420], [@b0425], [@b0430]  AcetaminophenAnalgesicsP-cresol-produce bacteria like*Clostridium difficile*High baseline microbial metabolite p-cresol compete for clearance by hepatic sulfotransferase and diminish the host's metabolic capacity for Phase II sulfonation of acetaminophen[@b0475], [@b0480]  SorivudineAntiviral drug*Bacteroidetes* sp. or enterobacteria (*Klebsiella pneumoniae*)Enzymatic convertion to (e)-5-(2-bromovinyl) uracil binding to related enzymes irreversibly to inhibit the metabolism of 5-fluorouracil and incite drug toxicity[@b0145], [@b0515], [@b0520]  IrinotecanAnticancer drugβ-glucuronidaseHydrolysis of SN-38-G of irinotecan (pro-drug) release SN-38 in the intestines which leads to gastrointestinal toxicity[@b0535], [@b0540], [@b0545], [@b0550]DiclofenacAnti-inflammatory drugMicrobial β-glucuronidase reactivate glucuronidated metabolite to cause gastrointestinal toxicity[@b0555]IndomethacinAnti-inflammatory drugs[@b0555], [@b0565]KetoprofenAnti-inflammatory drugs[@b0555]  StatinsHypolipidemicsBacteria like *Lactobacillus* sp. is involved in production of coprostanolMicrobially derived secondary bile acids may compete with simvastatin for hepatic uptake by SLCO1B1101 transporters[@b0550], [@b0590], [@b0595], [@b0600]  NitrazepamHypnotic, sedative, anticonvulsant and anxiolytic drugNitroreductaseBactical enzymatic convertion to 7-aminonitrazepam, followed by acetylation to 7-acetylaminonitrazepam in the liver[@b0625], [@b0630], [@b0635]

2.1. Mechanisms of microbial direct action on drug metabolism {#s0015}
-------------------------------------------------------------

### 2.1.1. Secreting microbial enzymes to transform prodrug molecules {#s0020}

The earliest reported example about prodrug activation by enzymatic activity of intestinal microbiota is the conversion of oral **prontosil** and **neoprontosil** into sulfanilamide. Prontosil is the first commercially available antibacterial drug that is lower polar than neoprontosil. This pharmacologically active metabolite is the reason why the two prodrugs exhibit antibacterial activities *in vivo* ([@b0180]), while minimal effect *in vitro*. Animal experiments using mouse models indicated that azoreductases produced by the colorectal microbiota are in charge of this modification ([@b0185]). It includes a two-step reaction, the formation of the hydrazo compound, followed by a reductive cleavage of the nitrogen bond ([@b0660]). Prontosil is converted to sulfanilamide also in the liver and kidney ([@b0155]). Moreover, prontosil injected intraperitoneally can experience gut bacterial metabolism by being excreted into the gastrointestinal tract via the bile. However, neoprontosil is excreted via the bile without reduction and absorption in the intestine due to its high polarity. Administration with antibiotics disturbing intestinal microbiota inhibits the activation of oral prontosil and neoprontosil into sulfanilamide in rats ([@b0185]).

**Sulfasalazine** is another sulfonamide drug that is metabolically activated by bacterial azoreductase enzymes ([@b0485]). Structurally intact sulfasalazine is scarcely absorbed from the upper intestine, but it undergoes bacterial azo reduction, and releases sulfapyridine (SP) and 5-aminosalicylic acid (5-ASA, mesalazine) in the colon. 5-ASA ([@b0270]), which is active in the colon, is used as an active anti-inflammatory moiety in treating inflammatory bowel disease (IBD), while systemically absorbed SP with its antibacterial and immunomodulatory effects, is considered to be useful in the treatment of rheumatoid arthritis ([@b0455]). Once sulfapyridine is absorbed in the colon, it may be the cause of side effects of sulfasalazine in some patients, such as rash, headache, and anorexia ([@b0485]). To obviate these adverse effects, **balsalazide** was synthesized from salicylic acid and 4-aminobenzoyl-b-alanine. It can be converted potently into 5-ASA also by intestinal microbiota -secreting azoreductase ([@b0070]). Another sulfasalazine analogue, **olsalazine**, is metabolized into two 5-ASAs by the same mechanism ([@b0690]). And as the active metabolites of three prodrugs, 5-ASA and SP further undergo acetylation performed by the gut microbiota in fecal suspensions from rats, guinea pigs, dogs and humans ([@b0355]). Notably, 5-ASA is acetylated into N-acetyl-5-aminosalicylic acid by individual bacteria under aerobic and anaerobic conditions in human faecal suspension ([@b0265], [@b0115]).

**Metronidazole**, mainly used to treat trichomoniasis, amoebiasis, and giardiasis ([@b0380]), is also a long-established antibacterial agent. In the liver, metronidazole is usually modified by side-chain oxidation and glucuronide formation to generate hydrophilic products. However, enzymes from *Clostridium perfringens* (an anaerobic gut bacterium) metabolize metronidazole into ring-cleavage products, N- (2-hydroxyethyl)-oxamic acid, and acetamide in the gut ([@b0360]). Another anthelmintic drug, **levamisole** is effective in both humans and animals, especially part active agent in colon cancer. It is metabolized into three thiazole ring-opened metabolites: levametabol-I, levametabol-II, and levametabol-III by human intestinal bacteria, mainly *Bacteroidetes and Clostridium* spp. under anaerobic conditions ([@b0595]).

In addition, several other drugs metabolized directly by intestinal microbes have been reported. **Omeprazole** is used to treat gastric ulcer, and can be reduced into corresponding sulfide metabolites by anaerobic bacteria such as *Bacteroides* strains *in vitro* conditions. But in fact, this bacterial metabolism is unlikely to occur because oral omeprazole is absorbed well, and does not reach the colon *in vivo* ([@b0715]). **Zonisamide,** an anticonvulsant clinically used to treat epilepsy, undergoes reduction of benzisoxazole ring performed by *Clostridium sporogenes* into 2-sulphamoylacetylphenol *in vivo* ([@b0345]). Two laxative drugs, **lactulose** and **sodium picosulfate** (Laxoberon), exert their effects through gut microbial metabolism. The former is converted by enzymes of several kinds of intestinal bacteria (*Bifidobacterium bifidum, Lactobacillus acidophilus* and *Clostridium perfringens*) into fructose and galactose followed by transformation into lactic and acetic acids. These end products promote the excretion of ammonia and amines into the feces to relieve hepatic encephalopathy through lowering the pH within the intestine ([@b0130], [@b0210]). The latter is metabolized into 4,49-(pyridin-2-ylmethanediyl) diphenol by arylsulfate sulfotransferase of *Eubacterium rectale* in the colon ([@b0325], [@b0315]). However, some anti-allergic drugs, such as diphenhydramine and chlorpheniramine, can cause or aggravate constipation by slowing intestinal peristalsis. This causes the feces to remain in the intestines for a long time and its moisture is excessively lower. Drinking 2500--3000 ml of water per day during medication or changing drugs with new antihistamines (loratadine and cetirizine) rather than taking laxatives, can improve this difficulty in defecation.

Some Chinese medicine ingredients are also metabolized by the intestinal microbial enzyme into the corresponding absorbable aglycones ([@b0735]), and their prototypes are poorly absorbed in the intestines. **Glycyrrhizin** is a sweet-tasting compound of the root of Glycyrrhiza glabra and Glycyrrhiza uralensis, and is used to treat hepatitis C in Japan. *Eubacterium*. sp. strain GLH completely metabolizes glycyrrhizin into 18b-glycyrrhetic acid which is absorbed well ([@b0240], [@b0310]). α-L-rhamnosidase and β-d-glucosidase from some bacteria (*Escherichia* sp., *Escherichia* sp., *Enterococcus* sp. and *Bacillus* sp.) can convert **buddleoside** into cancer-combating acacetin via acacetin-7-glucoside ([@b0635]). As the main ingredient of Panax ginseng, **ginsenoside Rb1** is metabolized into bioactive 20-O-b-D-glucopyranosyl-20 (S)-protopanaxadiol (compound K) by *Oscillibacter* spp., *Ruminococcus* spp., *Holdemania* spp., and *Sutterella* spp. ([@b0015], [@b0330]) **Sennosides** is converted to be 8-glucosyl-rheinanthrone or sennidin monoglucosides by reductase and 3-b-D-glucosidase from the gut microbiota, and the latter is further metabolized into rheinanthrone with purgative property in the distal intestine ([@b0235]). Several **flavonoid glycosides** ([@b0320]) (rutin, hesperidin, naringin, baicalin, wognoside, and poncirin) and **isoflavones** (daidzein, genistein ([@b0590]) and baicalin ([@b0650])are metabolized into their respective pharmacologically active metabolites by different intestinal microbiota and enzymes.

### 2.1.2. Expression of genetic element involved in drug inactivation {#s0025}

Orally administered cardiac glycoside drug **digoxin** is long known to be metabolized reductively and inactively into dihydrodigoxin and dihydrodigoxigenin by gut *Eggerthella lenta*. These two metabolites bind incompetently to the Na + -K + -ATPase of the myocardium in some patients ([@b0430], [@b0570], [@b0550]). These patients account for 10% of total population, and their gut microbiota convert over 40% of oral digoxin into inactive metabolites before its absorption ([@b0415]). Subsequent researches demonstrate that these people who can reduce digoxin, harbor some strains of *E. lenta* possessing a two-gene cytochrome-encoding operon, namely the cardiac glycoside reductase (cgr) operon ([@b0215]). This cgr operon works by producing a protein-Cgr1-Cgr2 complex that binds to digoxin, and accounts for digoxin\'s consequent reduction. And arginine is found to inhibit the reduction of digoxin in this study, so high-protein diet can help improve the efficacy of digoxin in patients who carry cgr + E. lentas ([@b0220]).

### 2.1.3. Sequestering drugs from the site of action {#s0030}

Normally, orally administered **levodopa** (L-dopa), as a precursor of dopamine, passes through the blood-brain barrier, and undergoes decarboxylation within the central nervous system (CNS). It can increase the level of dopamine in the CNS to exert its therapeutic effect on Parkinson's disease. However, one study on incubation of levodopa with rat cecal contents showed that most of the L--dopa was converted to m-tyramine or m-hydroxyphenylacetic acid through gut microbial decarboxylation process, which makes operative L--dopa reduced in the CNS ([@b0190]). Moreover, people infected with *Helicobacter pylori* are more common in patients with Parkinson's disease than in healthy controls. Subsequent studies have revealed that Helicobacter pylori is the major strain involved the bacterial decarboxylation ([@b0495], [@b0145], [@b0230]).

### 2.1.4. Developing bacterial transporters to change the efficacy of drugs {#s0035}

Bacteria have evolved multidrug transporters rather than highly selective drug-specific transporters to protect themselves from antibiotics and other antibacterials ([@b0420]). Great majority of these multidrug transporters belong to secondary transporters, using transmembrane electrochemical gradients, typically the proton motive force ([@b0515]), to drive drug efflux. The secondary transporters include five subclass transporter families, namely resistance-nodulation-division (RND), the major facilitator superfamily (MFS), the multidrug and toxic compound efflux (MATE), and the small multidrug resistance (SMR) superfamily ([@b0365]). A few belong to another transporters, the ABC transporters, which utilizes the energy released from ATP hydrolysis ([@b0100]). *Bacillus subtilis* and *Lactococcus lactis* harbour two types of transporters. Genome of the former encodes for at least 78 ABC transporters, of which BmrA belongs to the ABC family, and Bmr and Blt are listed as the secondary transporter ([@b0645]). Overexpression of any transporter in *B. subtilis* results in similar decreases in susceptibility to puromycin, chloramphenicol, doxorubicin, and fluoroquinolone antibiotics. However, *L. lactis* is found to express 40 putative drug transporters by *in silico* analysis of the genome ([@b0420]). Expression of the mdt (A) gene in *L. lactis* increased resistance to macrolides, streptogramins, lincosamides, and tetracyclines ([@b0490]). The presence of membrane protein BbmR in *Bifidobacterium breve* also increases its resistance to macrolides ([@b0010]). These various transporters have an effect on the efficacy of antibacterials.

2.2. Mechanisms of gut microbes on affecting host's capacity of metabolizing therapeutic drugs {#s0040}
----------------------------------------------------------------------------------------------

### 2.2.1. Producing microbial metabolites to compete enzymes with drugs {#s0045}

After exerting analgesic and antipyretic effects at the normal dose, **acetaminophen** is cleared in the form of conjugated metabolites, mainly through two phase II conjugation in the liver, namely glucuronidation and sulfation. However, a small part of excess acetaminophen can be transformed to N-acetyl-p-benzoquinone imine by CYP1A cytochrome ([@b0680]). N-acetyl-p-benzoquinone imine is further conjugated with hepatic glutathione (GSH) for detoxification. If GSH is absent, excess N-acetyl-p-benzoquinone imine is the cause of hepatotoxicity ([@b0745]). The pre-dose urinary concentration of a microbial metabolite, p-cresol, is related to the severity of acetaminophen hepatic toxicity ([@b0080]). As p-cresol and acetaminophen are both substrates for cytosolic sulfotransferases ([@b0170]), high baseline p-cresol produced by *Clostridium difficile* and others competes with acetaminophen for binding with the enzyme, leading to changes in the bioavailability of acetaminophen and its metabolites. This change induces the individual variation in acetaminophen metabolism and hepatic toxicity or failure ([@b0390]). Concurrently, the liver damage resulted by acetaminophen administration at night is more severe than that in the morning ([@b0335]). In a study with mice, Gong et al. reported that gut microbial metabolite, 1-phenyl-1,2-propanedione mediates diurnal variation of acetaminophen induced hepatotoxicity by exhausting hepatic GSH levels ([@b0195]). However, given the complexity of acetaminophen metabolism and the opposite result of an animal experiment to the above findings ([@b0505]), the effects of intestinal microbial metabolism on acetaminophen-induced hepatotoxicity require further investigation. Other bacterial metabolites, pyruvic acid and lactic acid, induce dendrite protrusion via GPR31 in intestinal CX3CR1^+^ mononuclear cells to enhance immune response, that may also influence drugs metabolism ([@b0465]). **Sorivudine**, a Japanese antiviral drug, produces a lethal effect through a mechanism similar to acetaminophen ([@b0480]). There are 18 acute deaths of patients related to co-administration of sorivudine and 5-fluorouracil, since sorivudine metabolite (e)-5-(2-bromovinyl) uracil is produced by fermentation of the *Bacteroidetes* sp. ([@b0470])or enterobacteria (*Klebsiella pneumoniae*) ([@b0030]). When sorivudine is concomitantly administered with oral **5-fluorouracil** prodrug (an anticancer drug), the metabolite binds to related enzymes irreversibly to inhibit the metabolism of 5-fluorouracil and incite its toxicity.

### 2.2.2. Promoting enterohepatic recirculation of drugs to metabolize drugs again {#s0050}

In enterohepatic recirculation, drugs entering the gastrointestinal tract are absorbed intestinally by the enterocytes, and subsequently are taken up into the hepatocytes via the portal vein ([@b0545]). When the drug is secreted into the intestine with bile, the intestinal bacteria can restore the active drug by hydrolysis and reduction or allow it to be reabsorbed to its site of action ([@b0445]). The metabolism of **Irinotecan** (CPT-11) is a good example of reactivation of drug by intestinal microbiota that has been inactivated in the liver. CPT-11 is an intravenous prodrug of the antineoplastic topoisomerase I inhibitor SN-38 for colorectal cancers ([@b0670]). It is known that irinotecan needs to be hydrolyzed by a carboxylesterase in tissues and serum to produce SN-38 ([@b0110]), an active metabolite exerting its pharmacological effects. SN-38 is conjugated by hepatic UDP-glucuronosyltransferase 1A1 into the inactive SN-38-G ([@b0300]). However, SN-38-G experiences biliary secretion into the intestines where it is deconjugated back to SN-38 by β-glucuronidase produced by bacteria, including *Escherichia coli*, *Bacteroides vulgatus*, and *Clostridium ramosum*. This reactivation leads to the dose-limiting adverse side effects, such as delayed diarrhea, weight loss, and suppression of the immune system ([@b0695]) [Fig. 1](#f0005){ref-type="fig"}. In line with SN-38, the enteropathic adverse reactions arise from protracted exposure to carboxylic acid-bearing non-steroidal anti-inflammatory drugs (NSAIDs) including **diclofenac**, **indomethacin** and **ketoprofen**. They are also related to the enterohepatic circulation of glucuronides and caused by reactivation of active metabolites by microbial β-glucuronidase ([@b0575]). Antibiotic treatment or application of inhibitors of microbial β-glucuronidase is reported to reduce the severe side effect inflicted by CPT-11 ([@b0540]) and by these NSAIDs, especially indomethacin in animal experiment. A subsequent study demonstrated that the absence of bacterial de-gluconuronidation resulted in reduced indomethacin reabsorption into the circulation, with increased elimination and a shortened half-life to follow ([@b0425]).Fig. 1Intestinal microflora participate in the enterohepatic recirculation of CPT-11, causing adverse side effects. (a) In tissues and serum, irinotecan is hydrolyzed by a carboxylesterase to produce SN-38, an active metabolite exerting its pharmacological effects. (b) In the liver, SN-38 is conjugated by UDP-glucuronosyltransferase 1A1 into the inactive SN-38-G. (c) SN-38-G experiences biliary secretion into the intestine. In the intestine, SN-38-G is deconjugated back to SN-38 by β-glucuronidase produced by bacteria, including Escherichia coli, Bacteroides vulgatus, and Clostridium ramosum.

### 2.2.3. Affecting bile acid metabolism to modulate systemic drug absorption {#s0055}

Due to their potent competition with 3-hydroxy-3-methyl-glutaryl-Co A (HMG-CoA) reductase ([@b0105])to reduce plasma levels of low-density lipoprotein cholesterol (LDL-C) ([@b0510]); **statins** are widely prescribed pro-drugs for treating hypercholesterolemia. Previously, great variations among individuals on therapeutic effects of statins are only partly attributed to genetic differences ([@b0435], [@b0675]). Subsequent studies demonstrated that gut microbiota are also responsible for statins bioavailability ([@b0295]). Gut microbiota-derived bile acids and statins share transporters in the gut and liver, such as organic anion transporter SLCO1B1 ([@b0475]). The gene encoding SLCO1B1 contains a single nucleotide polymorphism, rs4149056, which is associated with plasma concentrations of simvastatin acid and seven bile acids (7α-hydroxycholesterol, cholic acid, taurocholic acid, glycocholic acid, taurochenodeoxycholic acid, lithocholic acid, taurolithocholic acid). The genetic polymorphism may cause competition between **simvastatin** and bile acids for hepatic uptake by SLCO1B1 transporter ([@b0580]). Concurrently, it is also shown that incubation of lovastatin with human or rat fecalase preparations produces four metabolites ([@b0695]), including active β-hydroxy acid metabolite that is known to inhibit HMG-CoA reductase ([@b0740]). Thus, gut microbiota can influence the pharmacokinetics of simvastatin by competing with statins for absorbtion or co-metabolizing statins.

### 2.2.4. Affect the "components" of the host about drug metabolism {#s0060}

Emerging evidence indicates that the imbanlance of intestinal microbiota (germ-free mice and antibiotics-treated mice) alters expression levels of multiple drug-metabolizing enzymes and transporters in liver and kidney of mice, where most drugs are cleared. Among them, the decrease in CYP2B6 activity in human liver results in significant inter-individual differences in the metabolic activities towards cyclophosphamide, efavirenz and bupropio. Decreased protein expression level of BCRP also changes the pharmacokinetics of anticancer drugs, such as mitoxantrone and topotecan ([@b0370]). But, their related microbiota are unknown. The expression levels of drug-metabolizing enzymes (cytochromes, esterases, peptidases, phase I or II enzymes) and transporters (ATP-binding cassette, solute carrier family) in the gut are not only regulated by nuclear receptors ([@b0165])but also by intestinal microbiota. Changes in drug-metabolizing enzymes and transporters in the gut have a direct impact on the first-pass effect of midazolam, verapamil, felodipine and cyclosporine, even the fate of oral drugs (acetaminophen ([@b0685]), fosamprenavir, insulin ([@b0175]).

### 2.2.5. Producing a unique metabolite inducing hepatic further metabolism {#s0065}

The involvement of gut microbiota in the metabolism of **nitrazepam**, a hypnotic, sedative, anticonvulsant and anxiolytic drug, into its teratogenicity was demonstrated in experiments with rats ([@b0630]). Nitrazepam is transformed to 7-aminonitrazepam by nitroreductase from intestinal microbiota, followed by acetylation to 7-acetylaminonitrazepam in the liver ([@b0625]). Although reductive metabolism in rat liver is less potent than in gastrointestinal tract ([@b0530]), two metabolites are both teratogenic. The involvement of the gut microbiota in metabolism of above-mentioned drugs has been further demonstrated by studies in germ-free or antibiotic-treated rats. Metronidazole is the only drug with unchanged metabolism in these studies ([@b0500]). It is initially presumed that the specie involved in the metabolism of metronidazole is not sensitive to antibiotics. Currently metabolisms of many other drugs seem to also be related to the intestinal microbiota, but the specific bacteria or bacterial enzymes involved are unclear, and need to be further explored. Additionally, the mechanism by which the known intestinal microbiota affects drugs pharmacokinetics is by no means limited to the known. For example, the precise manner in which *Faecalibacterium prausnitzii* dictates **tacrolimus** dosing requirements is unknown ([@b0400]).

3. The possible impact of gut microbes on immune checkpoint inhibitors {#s0070}
======================================================================

In addition to the important role of gut microbiota in preventing disease, regulating immunity and metabolizing chemical or Chinese herbal medicine, these microbes have been shown to affect the immunomodulatory effect and side effect of immunotherapy. In 2015, two researches first confirmed that the composition of intestinal microbes determines the effectiveness of cancer immunotherapy in mice. Namely, the effect of the antibody of Ipilimumab targeting the immune checkpoint blocker CTLA-4 required *Bacteroides thetaiotaomicron* and *Bacteroides Fragilis* ([@b0665]), and *Bifidobacterium spp*. favored the efficacy of anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) monoclonal antibody ([@b0605]). Subsequent studies on human further confirmed the close relationship between intestinal bacteria and immunotherapy. Zivogel and his team revealed that gut microbiota, especially *Akkermansia muciniphila* which enhances the recruitment of CCR9 + CXCR3 + CD4+ T lymphocytes into tumor beds, has an impact on clinical benefit of immune checkpoint inhibitors targeting the PD-1/PD-L1 in patients with cancer ([@b0560]). Another two studies published in the same issue of Science on melanoma patients treated with PD-1 blockade respectively show that beneficial strains are more abundant in the guts of blockade-responding patients. The bacteria involved in the former are bacteria of the Ruminococcaceae family ([@b0200]), while the latter are *Bifidobacterium longum*, *Collinsella aerofaciens* and *Enterococcus faecium* ([@b0450]). These gut microbes may induce dendritic cells to release some cytokines which recruit more effector T cells to focus around the tumor. Gut microbiota may also be the reason why immune checkpoint inhibitors have clinical benefits for only 20--30% of treated cancer patients ([@b0055], [@b0700]). Therefore, appropriate strains can assist the immune system in responding to these treatments. Manipulating the gut microbiota is expected to be a new strategy to increase the activity of immunotherapeutics, and may also be used to reduce their side effects. Three related results were obtained with germ-free mice or antibiotics-treated mice, which reported improved response to anti-PD-1 therapy in mice given feces from responsive cancer patients. The mice receiving fecal transplants from responding patients also showed enhanced systemic and antineoplastic immunity ([@b0205], [@b0450], [@b0565]). Notably, significant and rapid cure of refractory immune checkpoint inhibitors (ICI)-associated colitis has been derived from fecal microbiota transplantation (FMT) with changes in gut microbial composition and T cell composition within the colonic mucosa of two cancer patients ([@b0705])). FMT benefits not only immunotherapy, but also other cancer treatments and reduces associated side effects, such as radiotherapy ([@b0095])and taking paclitaxel ([@b0065]). The list of immunological checkpoint inhibitors ([@b0035], [@b0160], [@b0710], [@b0075]) that are affected by the specific gut microbiota is showed in [Table 2](#t0010){ref-type="table"}.Table 2Immunological checkpoint inhibitors that are affected by the specific gut microbiota.TargetSpecific agentsClinical applicationBacterial Species involvedMechanismRef.PD-1PembrolizumabMelanoma*Dorea formicogenerans*Unmentioned[@b0715]PD-1UnidentifiedMelanoma*Clostridiales*increasing tumor immune infiltrates and density of CD8 + T cells[@b0725]PD-1UnidentifiedMelanoma*Ruminococcaceae*increasing density of CD8 + T cells[@b0690]PD-1UnidentifiedMelanoma*Bifidobacterium longum, Collinsella aerofaciens, Enterococcus faecium*improving tumor control, augmenting T cell responses and enhancing efficacy of anti-PD-L1 therapy[@b0670]PD-L1αPD-L1 mAbMelanomaSome *Bifidobacterium* speciesenhancing CD8(+) T cell priming and accumulation around the tumor[@b0720]CTLA-4IpilimumabMelanoma*Faecalibacterium prausnitzii*,\
*Dorea formicigenerans*reducing proportion of peripheral blood regulatory T cells[@b0730]CTLA-4IpilimumabMelanoma*Bacteroides thetaiotaomicron*, *Bacteroides fragilis*induced TH1 immune responses in the tumor-draining lymph nodes and promoting the maturation of intratumoral DCs[@b0650]PD-1/PD-L1UnidentifiedNon--small cell lung cancer, renal cell carcinoma and urothelial carcinoma*Akkermansia muciniphila*Enhancing the recruitment of CCR9 + CXCR3 + CD4 + T lymphocytes into tumor beds[@b0660]CTLA-4 and PD-1Ipilimumab plus nivolumabMelanoma*Fecalibacterium prausnitzii*, *Bacteroides thetaiotamicron*, *Holdemania filiformis*Unmentioned[@b0715][^1]

4. Existing limitations {#s0075}
=======================

It is known that intestinal microbes can modulate drug metabolism in several proposed ways including direct enzymatic effects on transform of drug molecules and affecting the host function to interfere with drug metabolism, such as changes in drug metabolizing enzymes, metabolic type and basal metabolism of host. Such studies accelerate the understanding of gut microbes and the correct application of drugs, but the animal models, germ-free mice and antibiotics-treated mice, have some limitations. Germ-free mice are abnormal mice with enlarged caecum, reduced villous thickness and villous capillary networks ([@b0620]), and they are not equivalent to normal mice without gut floma. In terms of metabolism, germ-free mice consume more calories and secrete more lipids ([@b0725]), which may make them more susceptible to low-grade inflammation. And germ-free mice show underdeveloped intestinal-associated lymphoid tissues, reduced production of secretory IgA and regulatory T cell, and imbalanced TH1-TH2 cell in immunity ([@b0555]). Germ-free mice also have abnormalities in signal transduction. Endocrine small molecules, such as dopamine which is critical to the development of the enteric nervous system, in germ-free mice are decreased ([@b0050]). Similarly antibiotics altenate not only intestinal microbiota but also the function of other organs in antibiotic-treated mice. Most experiments *in vitro* involve the incubation of drugs with bacterial suspensions prepared from rat or human cecal contents. Since the suspensions mix different bacteria that are in different positions and cannot contact each other in the gut *in vivo*, which may influence the order of different reactions, and some strains even cannot survive *in vitro*. So we can see that these operations do not accurately reflect the metabolism of the drug *in vivo*, although they allow us to discover the microbiota-mediated metabolites. Concurrently, the potential difference between *in vivo* and *in vitro* models of the gut microbiota should be taken into consideration when analyzing studies of drugs biotransformation, as some drugs are not metabolized *in vivo* but metabolized *in vitro*. These drugs are effectively absorbed before reaching the lower part of the intestine where containing more kinds of bacteria. Taken together, even if these models have certain reference value, it is very necessary for us to find more suitable models.

Given the wide variety of drugs affected by intestinal microbes, it is pivotal for personalized medicine to explore additional drugs affected by gut microbiota and their involved strains for further making mechanism clear. There is an overlap between different classes of drug metabolizing pathways. Thus, when exploring the unknown metabolic pathways of other drugs, it is conceivable that these pathways may be partially similar to the known pathways described above. Sometimes drug treatment outcomes of two individuals are different, although they all contain the related microorganisms and enzymes. Other factors may be involved in, e.g. microbial-induced host gene quantitative or qualitative changes, especially at the level of epigenetic regulation. Concurrently, although intestinal microbial regulation of microRNA in the brain ([@b0260])and effect on drug metabolism enzymes and transporters in host liver and kidney ([@b0375]) have been confirmed, the mechanisms by which microbes cause these variations and the optimal treatments are in their initial stages.

5. Future directions {#s0080}
====================

On the basis of existing research results, we propose these promising research points: (I) At present, there are only over 30 drugs that are known to be closely related to the intestinal microbiota, and we need to further clarify other drugs affected by the microbiota, and the mechanism involved. (II) In addition to germ-free mice and antibiotic-treated mice, studies on microbiota and drug metabolism require more scientific animal models. (III) There may be not only one kind strain involved in when intestinal microbiota affects drug metabolism and side effects, but may several "related" microbiota implicated in, or an equilibrium state of the whole microbiota related to. This conclusion may be different depending on the specific drugs taken. (IV) It is necessary to strengthen the *in vivo* study on the interaction of microbiota, host intestinal epithelial cells and drugs in the intestinal microenvironment, especially the microbical regulation of genes related to drug metabolism in the host. (V) By analyzing the relationship between individual intestinal microbiota traits (diversity, composition, metabolites) and drug metabolism, it is expected to develop a estimating system for bacterial population (before administration) related to drug use efficiency and side effects. (VI) When interfering with intestinal microbes, it is warranted to choose the right means based on the principle of completeness to restore intestinal microbiota balance, rather than only supplement what is short. Considering that FMT has made progress in the treatment of intestinal diseases ([@b0250], [@b0255], [@b0290]), we can expect whether transplantation of normal human microbiota to patients with abnormal drug metabolism also has therapeutic effects. But, special attention should be paid during the operation to prevent infection which may endanger the patient\'s life. (VII) On the basis of clarifying the particular microbiota that affects the bioavailability of a drug, it may be considered to explore the strategy of taking the drug in combination with this related microbiota, but to ensure that this microbiota survives after entering the intestine without disturbing the overall microbiota balance (avoiding causing new problems), and acts on the same part of the intestinal tract with the drug. (VIII) Similarly, other means of regulating the microbiota of a patient may also be considered, such as co-administration of drug and prebiotics or synbiotics that are beneficial to the microbiota. It is necessary to explore new microbial inhibitors, microbial enzyme inhibitors or microbiota-derived molecules (active metabolites or microbial gene products) which are equally beneficial to the drug, when the microbiota is not conducive to the metabolism of the drug. (IX) Co-administration of sorivudine and 5-fluorouracil is known to incite acute deaths. More drug-drug interactions involved in intestinal microbiota should be investigated. Answering these questions is conducive to the continued research of drugs and improving individualized medicine.
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[^1]: *mAb* monoclonal antibody; *TH1* T helper 1; *DCs* dendritic cells.
